Biostem Technologies Inc (BSEM)

$6.55 -0.50 (-7.03%)
Market Cap 117.89M
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio 9.10
Forward PE 13.83
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 183,900
Avg Vol 53,030
Day's Range N/A - N/A
Shares Out 16.75M
Stochastic %K 26%
Beta -0.29
Analysts Strong Buy
Price Target $35.50

Company Profile

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding s...

Industry: Biotechnology
Sector: Healthcare
Phone: 954 380 8342
Address:
2836 Center Port Circle, Pompano Beach, United States
Monk1212
Monk1212 Aug. 18 at 11:25 PM
$BSEM the stock is down YTD, but share price ≠ business performance. BioStem grew from $4M to $332M revenue run-rate with 96% gross margins, $31M cash, and expanding insurance coverage. Management is about to file the final Form 10 — uplisting could be next. Cheap entry point here.
1 · Reply
GlobalInsights
GlobalInsights Aug. 18 at 9:09 PM
$BSEM Yr to date shares down 52%
1 · Reply
Monk1212
Monk1212 Aug. 18 at 6:30 PM
$BSEM These comments are from earnings call, q2 revenue impact was due to delay to include Biostem products on the final ASP list: Reimbursement Uncertainty Hurt Q2, But Is Resolving • Management explained that BioStem’s products weren’t on the preliminary Medicare ASP pricing list, which created “perceived reimbursement risk” and delayed provider adoption early in Q2.  • Once the products were included on the final ASP list, the market response improved, and July and August showed early sales recovery.  Strategic Mitigation Efforts • To counter reimbursement and pricing headwinds, BioStem is targeting larger mobile wound care providers through Venture Medical — providers offering stable, contract-based relationships.  • They plan to scale internal sales, broaden geographic coverage, and diversify channels.
1 · Reply
GlobalInsights
GlobalInsights Aug. 18 at 3:11 PM
$BSEM https://www.cfgi.com/resources/articles/cfos-guide-to-significant-deficiencies-and-material-weaknesses/
1 · Reply
GlobalInsights
GlobalInsights Aug. 18 at 2:45 PM
$BSEM Investing in pink sheet stocks carries significant risks compared to investing in stocks traded on major exchanges like the NYSE or Nasdaq. Pink sheet companies operate with lower levels of regulation and transparency, which can make it challenging for investors to assess their true financial health and prospects. The only way to resolve material weaknesses in financial systems that are flawed is to change the financial system process and procedures then test that they work over several quarters. Once that is done the changes are applied to past yrs financial reporting and they then restate them. Once that is done auditors can sign off and take away the designation of material weaknesses. Once that is done they can complete any up-listing process but not before. So if they have fixed things then it will be another 6+ months to prove the fixes work, once that is done they can restate past financial reporting. I went through this exact thing for a company i was vice chairman of.
1 · Reply
CactusRumble
CactusRumble Aug. 18 at 2:16 PM
$BSEM
0 · Reply
GlobalInsights
GlobalInsights Aug. 18 at 1:55 PM
$BSEM Specific services that will require prior authorization are skin and tissue substitutes, electrical nerve stimulator implants, and knee arthroscopy. There is genuine concern about the costs of some of these items and services. A recent New York Times article highlighted pricey medical products, including paper-thin bandages made of dried bits of placenta, for Medicare patients.
2 · Reply
Monk1212
Monk1212 Aug. 18 at 12:03 PM
$BSEM BSEM $NVDA $TSLA $AMD $PLTR BioStem Key Stats Market Cap: $117M | EV: ~$90M Revenue (TTM): $332.45M | EPS: $1.41 Gross Margin: 96% | Net Margin: 10% Cash: $31M vs Debt: $4.3M Growth Rev grew $4M → $332M in 4 yrs Final Form 10 expected soon → uplisting next Private insurer coverage expanding = stronger revenues Why Watch EV/Revenue 0.27x | EV/EBITDA <3x Strong balance sheet + big catalysts ahead
0 · Reply
Monk1212
Monk1212 Aug. 18 at 10:45 AM
$BSEM The Trump administration’s plan to test prior authorization in traditional Medicare is not directly aimed at BioStem Technologies’ wound care and skin substitute products. While prior authorization could add documentation requirements for providers if extended to this category, BioStem is already engaged with CMS on reimbursement reforms and is well-positioned to adapt. At this stage, the pilot program poses no immediate material impact on BioStem’s revenue or growth outlook. However, investors should continue monitoring CMS policy developments, as broader Medicare changes can influence provider adoption and sentiment around smaller MedTech firms.
0 · Reply
Buying_another
Buying_another Aug. 17 at 6:37 PM
$BSEM $CHSN $CYCU $GNPX $TROLGA.X 🥰
0 · Reply
Latest News on BSEM
No data available.
Monk1212
Monk1212 Aug. 18 at 11:25 PM
$BSEM the stock is down YTD, but share price ≠ business performance. BioStem grew from $4M to $332M revenue run-rate with 96% gross margins, $31M cash, and expanding insurance coverage. Management is about to file the final Form 10 — uplisting could be next. Cheap entry point here.
1 · Reply
GlobalInsights
GlobalInsights Aug. 18 at 9:09 PM
$BSEM Yr to date shares down 52%
1 · Reply
Monk1212
Monk1212 Aug. 18 at 6:30 PM
$BSEM These comments are from earnings call, q2 revenue impact was due to delay to include Biostem products on the final ASP list: Reimbursement Uncertainty Hurt Q2, But Is Resolving • Management explained that BioStem’s products weren’t on the preliminary Medicare ASP pricing list, which created “perceived reimbursement risk” and delayed provider adoption early in Q2.  • Once the products were included on the final ASP list, the market response improved, and July and August showed early sales recovery.  Strategic Mitigation Efforts • To counter reimbursement and pricing headwinds, BioStem is targeting larger mobile wound care providers through Venture Medical — providers offering stable, contract-based relationships.  • They plan to scale internal sales, broaden geographic coverage, and diversify channels.
1 · Reply
GlobalInsights
GlobalInsights Aug. 18 at 3:11 PM
$BSEM https://www.cfgi.com/resources/articles/cfos-guide-to-significant-deficiencies-and-material-weaknesses/
1 · Reply
GlobalInsights
GlobalInsights Aug. 18 at 2:45 PM
$BSEM Investing in pink sheet stocks carries significant risks compared to investing in stocks traded on major exchanges like the NYSE or Nasdaq. Pink sheet companies operate with lower levels of regulation and transparency, which can make it challenging for investors to assess their true financial health and prospects. The only way to resolve material weaknesses in financial systems that are flawed is to change the financial system process and procedures then test that they work over several quarters. Once that is done the changes are applied to past yrs financial reporting and they then restate them. Once that is done auditors can sign off and take away the designation of material weaknesses. Once that is done they can complete any up-listing process but not before. So if they have fixed things then it will be another 6+ months to prove the fixes work, once that is done they can restate past financial reporting. I went through this exact thing for a company i was vice chairman of.
1 · Reply
CactusRumble
CactusRumble Aug. 18 at 2:16 PM
$BSEM
0 · Reply
GlobalInsights
GlobalInsights Aug. 18 at 1:55 PM
$BSEM Specific services that will require prior authorization are skin and tissue substitutes, electrical nerve stimulator implants, and knee arthroscopy. There is genuine concern about the costs of some of these items and services. A recent New York Times article highlighted pricey medical products, including paper-thin bandages made of dried bits of placenta, for Medicare patients.
2 · Reply
Monk1212
Monk1212 Aug. 18 at 12:03 PM
$BSEM BSEM $NVDA $TSLA $AMD $PLTR BioStem Key Stats Market Cap: $117M | EV: ~$90M Revenue (TTM): $332.45M | EPS: $1.41 Gross Margin: 96% | Net Margin: 10% Cash: $31M vs Debt: $4.3M Growth Rev grew $4M → $332M in 4 yrs Final Form 10 expected soon → uplisting next Private insurer coverage expanding = stronger revenues Why Watch EV/Revenue 0.27x | EV/EBITDA <3x Strong balance sheet + big catalysts ahead
0 · Reply
Monk1212
Monk1212 Aug. 18 at 10:45 AM
$BSEM The Trump administration’s plan to test prior authorization in traditional Medicare is not directly aimed at BioStem Technologies’ wound care and skin substitute products. While prior authorization could add documentation requirements for providers if extended to this category, BioStem is already engaged with CMS on reimbursement reforms and is well-positioned to adapt. At this stage, the pilot program poses no immediate material impact on BioStem’s revenue or growth outlook. However, investors should continue monitoring CMS policy developments, as broader Medicare changes can influence provider adoption and sentiment around smaller MedTech firms.
0 · Reply
Buying_another
Buying_another Aug. 17 at 6:37 PM
$BSEM $CHSN $CYCU $GNPX $TROLGA.X 🥰
0 · Reply
AITechBot
AITechBot Aug. 17 at 6:32 PM
$BSEM $CHSN $CYCU $GNPX $TROLGA.X Confirmed from a few crypto Chats that TROLGA is about go Parabolic🚀🚀✅✅✅!!!
1 · Reply
Whiskey1679
Whiskey1679 Aug. 17 at 6:28 PM
Whiskey's Picks out tomorrow morning!! High Volume: $TROLGA.X $BSEM $CHSN $GNPX $CYCU
1 · Reply
GlobalInsights
GlobalInsights Aug. 17 at 6:08 PM
$BSEM More barriers to overcome: https://finance.yahoo.com/news/trump-administration-tiptoes-into-testing-prior-authorization-in-traditional-medicare-143012089.html
1 · Reply
RStash
RStash Aug. 17 at 12:31 PM
$BSEM wow, very low volume this morning but the price seems to be holding steady
0 · Reply
Monk1212
Monk1212 Aug. 17 at 12:18 PM
$BSEM Comments from earnings call, q2 revenue impact was due to delay to include Biostem products on the final ASP list: Reimbursement Uncertainty Hurt Q2, But Is Resolving • Management explained that BioStem’s products weren’t on the preliminary Medicare ASP pricing list, which created “perceived reimbursement risk” and delayed provider adoption early in Q2.  • Once the products were included on the final ASP list, the market response improved, and July and August showed early sales recovery.  Strategic Mitigation Efforts • To counter reimbursement and pricing headwinds, BioStem is targeting larger mobile wound care providers through Venture Medical — providers offering stable, contract-based relationships.  • They plan to scale internal sales, broaden geographic coverage, and diversify channels.
0 · Reply
Monk1212
Monk1212 Aug. 17 at 12:01 PM
$BSEM A material weakness is worth noting, but management has already submitted the Form 10 and a few amendments to address SEC questions. They’ve said they now have full clarity and are working to make the next amendment perfect and final, so the next step is uplisting without further delays. Meanwhile, they are seeing early revenue recovery with new sales strategies, rapidly expanding into new regions, and getting BioStem products onto major private insurer coverage lists. That provides a buffer against CMS changes, which affect the entire industry, not just BioStem. This team has grown the company from $4M to $350M+ annually and is clearly firing on all cylinders to keep growth strong. With over $100M YTD 2025 revenue, ~99% margins, strong cash, and an EV of just $70M, the valuation looks very attractive, and we are now very close to a Nasdaq uplisting. I don’t want to lose sight of where this could be headed.
0 · Reply
GlobalInsights
GlobalInsights Aug. 16 at 6:50 PM
$BSEM In essence, a material weakness is a red flag indicating a potential breakdown in a company's financial controls, carrying a high risk of misstated financial information and serious repercussions for the company's financial health, reputation, and relationship with investors and regulators.
0 · Reply
Monk1212
Monk1212 Aug. 16 at 11:15 AM
$BSEM I get the frustration, but it’s not fair to say management has “lost all credibility.” This team grew BioStem from just $4M to $350M+ in revenue run-rate, so why would they spoil their own baby? They’ve already filed the Form 10 and multiple amendments — this time they have full clarity on SEC comments and are preparing a complete amendment, likely in final review, to avoid further delays. At the same time, management is implementing new sales strategies with Venture Medical to drive growth and offset CMS-related headwinds. The CMS decision impacts the entire industry, not just BioStem, which is why they’re also making sure products are broadly covered by private insurers to protect revenues. With $100M+ YTD 2025 revenue, ~99% gross margins, strong cash, and an enterprise value of ~$70M, the company looks very undervalued. Uplisting news could come soon, and I don’t want to overlook BioStem at this stage. The fundamentals are too strong for the valuation gap to last forever.
0 · Reply
GlobalInsights
GlobalInsights Aug. 15 at 7:43 PM
$BSEM The hype continues and people buying this company are buying a leadership team that lacks the transparency that allows investors to make informed decisions. They provided no detailed update on their material weakness. And no update on their FDA warning letter which is still not closed. Their business model succeeded because of a loophole in reimbursement, that loophole is about to close and their selling prices are about to drop by 80+% and posters here are still trying to justify and support management. Their business model fact the CFO was replaced should be a warning as to what’s to come. But don’t believe me, I’m wrong a lot. Anyway, buy SLS if you want to make a high risk stock that is about to have a binary event, either a 1 or a 0
0 · Reply
Monk1212
Monk1212 Aug. 15 at 6:41 PM
$BSEM Zack Review - BioStem is a leader in regenerative medicine, using perinatal tissue to create top-tier allografts like Vendaje and Vendaje AC. Mission: develop the most effective regenerative products in the world — and they’re well on their way. Q2 had a hiccup (-$0.03 EPS, rev down 34%) mainly due to Medicare reimbursement (MACS LCD) uncertainty. Margins still huge at 98.6%, and cash jumped to $30.8M from $20.6M last quarter 💰. Management is pushing hard to resolve the LCD review and get full coverage for their products. Big catalyst ahead: Diabetic foot ulcer trial (BioREtain Amnion Chorion) — patient enrollment DONE, results expected Q4 2025 📅. Their products keep outperforming competitors and gaining traction with doctors & patients. Zacks lowered PT to $25.50 after Q2, but long-term picture stays strong. With LCD resolved + expansion in wound care, the upside could be massive. The best for $BSEM is still to come. Patience will pay. 🩹📈
0 · Reply
ZacksSCR
ZacksSCR Aug. 15 at 5:09 PM
$BSEM Expands Margins https://buff.ly/VhIPLdZ
2 · Reply
Mostlybad
Mostlybad Aug. 15 at 2:40 PM
$BSEM 🤢 The bull case was that the company is an innovator, has a cost advantage and offers a better product. Is that still true? Why are they losing market share to competitors?
2 · Reply